These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

298 related articles for article (PubMed ID: 30589027)

  • 1. Treatment of high-grade gliomas using escalating doses of hypofractionated simultaneous integrated boost-intensity-modulated radiation therapy in combination with temozolomide: A modified Phase I clinical trial.
    Ge X; Xue X; Liu H; Wang Y; Xiao Z; Tian L; Chang X; Lin Q; Yu J
    J Cancer Res Ther; 2018; 14(7):1482-1491. PubMed ID: 30589027
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy of moderately hypofractionated simultaneous integrated boost intensity-modulated radiotherapy combined with temozolomide for the postoperative treatment of glioblastoma multiforme: a single-institution experience.
    Zhong L; Chen L; Lv S; Li Q; Chen G; Luo W; Zhou P; Li G
    Radiat Oncol; 2019 Jun; 14(1):104. PubMed ID: 31196126
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I study of hypofractionated intensity modulated radiation therapy with concurrent and adjuvant temozolomide in patients with glioblastoma multiforme.
    Jastaniyah N; Murtha A; Pervez N; Le D; Roa W; Patel S; Mackenzie M; Fulton D; Field C; Ghosh S; Fallone G; Abdulkarim B
    Radiat Oncol; 2013 Feb; 8():38. PubMed ID: 23425509
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase I trial of hypofractionated intensity-modulated radiotherapy with temozolomide chemotherapy for patients with newly diagnosed glioblastoma multiforme.
    Chen C; Damek D; Gaspar LE; Waziri A; Lillehei K; Kleinschmidt-DeMasters BK; Robischon M; Stuhr K; Rusthoven KE; Kavanagh BD
    Int J Radiat Oncol Biol Phys; 2011 Nov; 81(4):1066-74. PubMed ID: 20932651
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Dose-escalation by hypofractionated simultaneous integrated boost IMRT in unresectable stage III non-small-cell lung cancer.
    Zhang Q; Cai XW; Feng W; Yu W; Fu XL
    BMC Cancer; 2022 Jan; 22(1):96. PubMed ID: 35065627
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Simultaneous Integrated Boost for Radiation Dose Escalation to the Gross Tumor Volume With Intensity Modulated (Photon) Radiation Therapy or Intensity Modulated Proton Therapy and Concurrent Chemotherapy for Stage II to III Non-Small Cell Lung Cancer: A Phase 1 Study.
    Jeter MD; Gomez D; Nguyen QN; Komaki R; Zhang X; Zhu X; O'Reilly M; Fossella FV; Xu T; Wei X; Wang H; Yang W; Tsao A; Mohan R; Liao Z
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):730-737. PubMed ID: 29248169
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Hypofractionated intensity-modulated radiotherapy using simultaneous integrated boost technique with concurrent and adjuvant temozolomide for glioblastoma.
    Yoon SM; Kim JH; Kim SJ; Khang SK; Shin SS; Cho YH; Jwa E; Park JH; Ahn SD
    Tumori; 2013; 99(4):480-7. PubMed ID: 24326836
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hypofractionated intensity modulated radiotherapy with temozolomide in newly diagnosed glioblastoma multiforme.
    Ammirati M; Chotai S; Newton H; Lamki T; Wei L; Grecula J
    J Clin Neurosci; 2014 Apr; 21(4):633-7. PubMed ID: 24380758
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chemoradiotherapy with temozolomide after high-dose methotrexate for primary CNS lymphoma: a multicenter phase I study of a response-adapted strategy.
    Chiesa S; Hohaus S; Falcinelli L; D'Alò F; Martelli MF; Manfrida S; Beghella Bartoli F; Colosimo C; Valentini V; Aristei C; Balducci M
    Ann Hematol; 2020 Oct; 99(10):2367-2375. PubMed ID: 32816079
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Temozolomide during and after radiation therapy for WHO grade III gliomas: preliminary report of a prospective multicenter study.
    Kim YH; Park CK; Cho WH; Kim IA; Moon S; Choe G; Park SH; Kim IH; Kim DG; Jung HW; Lee MM; Bae SH; Cha SH; Kim CY
    J Neurooncol; 2011 Jul; 103(3):503-12. PubMed ID: 20862518
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Feasibility and outcomes of hypofractionated simultaneous integrated boost-intensity modulated radiotherapy for malignant gliomas: a preliminary report.
    Cha J; Suh CO; Park K; Chang JH; Lee KS; Kim SH; Chang JS; Kim JH; Suh YG; Kim JW; Cho J
    Yonsei Med J; 2014 Jan; 55(1):70-7. PubMed ID: 24339289
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hypofractionated image-guided IMRT in advanced pancreatic cancer with simultaneous integrated boost to infiltrated vessels concomitant with capecitabine: a phase I study.
    Passoni P; Reni M; Cattaneo GM; Slim N; Cereda S; Balzano G; Castoldi R; Longobardi B; Bettinardi V; Gianolli L; Gusmini S; Staudacher C; Calandrino R; Di Muzio N
    Int J Radiat Oncol Biol Phys; 2013 Dec; 87(5):1000-6. PubMed ID: 24267968
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Accelerated intensity-modulated radiotherapy plus temozolomide in patients with glioblastoma: a phase I dose-escalation study (ISIDE-BT-1).
    Massaccesi M; Ferro M; Cilla S; Balducci M; Deodato F; Macchia G; Valentini V; Morganti AG
    Int J Clin Oncol; 2013 Oct; 18(5):784-91. PubMed ID: 22892797
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Simultaneous integrated boost intensity-modulated radiotherapy for locally advanced head-and-neck squamous cell carcinomas: II--clinical results.
    Lauve A; Morris M; Schmidt-Ullrich R; Wu Q; Mohan R; Abayomi O; Buck D; Holdford D; Dawson K; Dinardo L; Reiter E
    Int J Radiat Oncol Biol Phys; 2004 Oct; 60(2):374-87. PubMed ID: 15380569
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Simultaneous integrated boost intensity-modulated radiotherapy (SIB-IMRT) combined with nimotuzumab for locally advanced esophageal squamous cell carcinoma (ESCC): A phase II clinical trial.
    Wang L; Liu L; Cao Y; Chen X; Liu S; Li X; Han J; Wang Q; Han C
    BMC Cancer; 2024 Jun; 24(1):679. PubMed ID: 38831450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Hypofractionated radiotherapy with simultaneous integrated boost (SIB) plus temozolomide in good prognosis patients with glioblastoma: a multicenter phase II study by the Brain Study Group of the Italian Association of Radiation Oncology (AIRO).
    Scoccianti S; Krengli M; Marrazzo L; Magrini SM; Detti B; Fusco V; Pirtoli L; Doino D; Fiorentino A; Masini L; Greto D; Buglione M; Rubino G; Lonardi F; Migliaccio F; Marzano S; Santoni R; Ricardi U; Livi L
    Radiol Med; 2018 Jan; 123(1):48-62. PubMed ID: 28879459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Accelerated hypofractionated intensity-modulated radiotherapy with concurrent and adjuvant temozolomide for patients with glioblastoma multiforme: a safety and efficacy analysis.
    Panet-Raymond V; Souhami L; Roberge D; Kavan P; Shakibnia L; Muanza T; Lambert C; Leblanc R; Del Maestro R; Guiot MC; Shenouda G
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):473-8. PubMed ID: 18554821
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Phase 2 trial of hypofractionated high-dose intensity modulated radiation therapy with concurrent and adjuvant temozolomide for newly diagnosed glioblastoma.
    Iuchi T; Hatano K; Kodama T; Sakaida T; Yokoi S; Kawasaki K; Hasegawa Y; Hara R
    Int J Radiat Oncol Biol Phys; 2014 Mar; 88(4):793-800. PubMed ID: 24495592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Phase I Trial of Intensity-Modulated Hyperfractionated Radiotherapy Boost with Concurrent Chemotherapy Immediately Following Standard Chemoradiotherapy in Patients Primarily with Advanced Intra-thoracic/Cervical Esophageal Squamous Cell Carcinomas.
    Cheng N; Liu Y; Zhao G; Xu Y; Zhang T; Chen Y; Yan G; Hu Y; Yao S; Wang Z; Wang C; Chen Z; Hu Z; Liu D; Chen T
    Int J Radiat Oncol Biol Phys; 2020 Feb; 106(2):340-348. PubMed ID: 31655197
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase II trial of hypofractionated IMRT with temozolomide for patients with newly diagnosed glioblastoma multiforme.
    Reddy K; Damek D; Gaspar LE; Ney D; Waziri A; Lillehei K; Stuhr K; Kavanagh BD; Chen C
    Int J Radiat Oncol Biol Phys; 2012 Nov; 84(3):655-60. PubMed ID: 22483738
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.